Company news
Johnson & Johnson (NYSE:JNJ) news
Every Johnson & Johnson press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 ins...
September 13, 2026
Johnson & Johnson : New overall survival data and treatment experience improvements reinforce the impact of RYBREVANT® (amivantamab-vmjw)...
September 11, 2026
Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses
September 10, 2026
Johnson & Johnson : presents new data at IMS 2026 highlighting its industry-leading multiple myeloma portfolio, with the goal of advancin...
September 9, 2026
Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026
September 8, 2026
New clinical evidence presented at PAINWeek 2026 demonstrates the powerful, long-lasting relief of TYLENOL® with Naproxen in post-surgica...
September 8, 2026
Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit
September 2, 2026
FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark adv...
August 24, 2026
Louisiana Jury Issues $10 Million Verdict in Talc-Related Mesothelioma Case Against Johnson & Johnson
August 24, 2026
Johnson & Johnson : Announces New Global Classification System for Surgical Outcomes
August 24, 2026
European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma, offe...
August 21, 2026
Johnson & Johnson : Publishes New Future of Digital Surgery Report to Help Define the Emerging Field of Surgical Intelligence
August 18, 2026
Johnson & Johnson Announces MONARCH QUEST 3, Advancing the Latest in Robotically-Assisted Bronchoscopy
August 18, 2026
Johnson & Johnson : Announces MONARCH™ QUEST 3, Advancing the Latest in Robotically-Assisted Bronchoscopy
August 17, 2026
Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
August 10, 2026
Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medic...
August 4, 2026
Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class ...
July 30, 2026
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation
July 29, 2026
Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Throu...
July 29, 2026
Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation
July 27, 2026
FDA Approves TYLENOL® with Naproxen, the First and Only Over-the-Counter Fixed-Dose Combination of Acetaminophen (650 mg) and Naproxen So...
July 24, 2026
TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refract...
July 23, 2026
Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System
July 22, 2026
Johnson & Johnson : Second Quarter 2026 2026 Second-Quarter Earnings Transcript
July 17, 2026
Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award
July 16, 2026
Johnson & Johnson : Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award
July 16, 2026
DePuy Synthes Acquires Expanding Innovations™
July 16, 2026
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026
July 15, 2026
Illinois Appellate Court Affirms $45 Million Mesothelioma Verdict Against Johnson & Johnson and Kenvue
July 10, 2026
Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform
July 8, 2026
Johnson & Johnson - DePuy Synthes Appoints Christina Zamarro as Chief Financial Officer
June 30, 2026
Johnson & Johnson : DePuy Synthes Appoints Christina Zamarro as Chief Financial Officer
June 29, 2026
Johnson & Johnson presents new IMAAVY®▼ (nipocalimab) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained dis...
June 26, 2026
Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained...
June 26, 2026
CHMP recommendation advances Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab as a potential standard of care for relapsed/r...
June 26, 2026
Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform
June 25, 2026
Johnson & Johnson : Highlights Positive Results from MEMBRANE Trial Published in JAMA Neurology
June 19, 2026
Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida
June 15, 2026
New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line rela...
June 13, 2026
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific c...
June 13, 2026
Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients
June 11, 2026
IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmu...
June 11, 2026
Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial
June 10, 2026
Johnson & Johnson : DePuy Synthes Launches VELYS™ Hip Navigation with AI to Support Intraoperative Consistency and Efficiency in Total Hi...
June 9, 2026
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
June 8, 2026
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a P...
June 3, 2026
Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
June 3, 2026
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of met...
May 31, 2026
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer wh...
May 31, 2026
Johnson & Johnson : RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced hea...
May 31, 2026